Please assess the completion status of the following clinical trial:

Trial Title: Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~The investigators will enroll Veterans who fulfill the following criteria:~* stage 3, 4, or 5 CKD (estimated glomerular filtration rate of less than 60 ml/min/1.73 m2) on at least two separate occasions greater than 3 months apart; and~* candidates for EPO therapy as per the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative guidelines (hemoglobin \< 10 gm/dL and anemia of CKD).~Exclusion Criteria:~The investigators will exclude any Veteran who meets any of the following criteria:~1. pregnant, planning to become pregnant in the next year, or breast feeding;~2. uncontrolled hypertension (blood pressure \> 180/100 mm Hg despite optimal antihypertensive medications);~3. active gastrointestinal bleeding (visible blood or positive tests for stool occult blood accompanied by a decrease in hemoglobin);~4. likely to have EPO resistance;~5. an adverse cardiovascular event in the prior three months;~6. active or recent (within the last 3 months) severe, systemic infection;~7. active inflammatory disease such as lupus, rheumatoid arthritis, or vasculitis requiring immunosuppressive or immunomodulatory medications;~8. history of solid organ transplantation;~9. expected off-dialysis survival of less than one year (as determined by the estimated glomerular filtration slope and the treating physician;~10. active cancer (undergoing chemotherapy or radiation within the last 3 months) or primary bone marrow disease such as myelofibrosis; or~11. a contraindication for an MRI or individuals who cannot comply with the study protocol. The investigators will exclude healthy subjects that meet a, b, f, g, h, or j.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low dose erythropoietin (Type: PLACEBO_COMPARATOR): Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
- High dose erythropoietin (Type: EXPERIMENTAL): Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).